CDK4/6 Inhibitors in Advanced Breast Cancer – ctDNA Analysis

CDK4/6 Inhibitors in Advanced Breast Cancer – ctDNA Analysis

September 4, 2025 Dr. Jennifer Chen Health

HereS the details extracted from the ‌provided text, formatted as a list of bibliographic entries:

31. Klocker, E. V. et ⁢al. Clinical applications of next-generation sequencing-based ctDNA⁤ analyses in breast cancer: defining⁢ treatment targets and dynamic changes during disease progression. Mol. Oncol. 191897-1917 ‌(2025).
PubMed: lookup?&title=Clinical%20applications%20of%20next-generation%20sequencing-based%20ctDNA%20analyses%20in%20breast%20cancer%3A%20defining%20treatment%20targets%20and%20dynamic%20changes%20during%20disease%20progression&journal=Mol.%20Oncol.&volume=19&pages=1897-1917&publicationyear=2025&author=Klocker%2CEV”>http://scholar.google.com/scholarlookup?&title=Clinical%20applications%20of%20next-generation%20sequencing-based%20ctDNA%20analyses%20in%20breast%20cancer%3A%20defining%20treatment%20targets%20and%20dynamic%20changes%20during%20disease%20progression&journal=Mol.%20Oncol.&volume=19&pages=1897-1917&publicationyear=2025&author=Klocker%2CEV

32. van Dessel, L. ⁣F.‌ et al.Submission ⁣of circulating tumor DNA in ‌prospective clinical oncology trials-standardization of preanalytical conditions. Mol.Oncol. 11295-304 (2017).
⁣
PubMed:‍ http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527445
* Google‌ Scholar:

, , , , , , , ,